Patent ID: 8741844

Claim:
A method for inhibiting or treating coagulation disorders resulting from side effects of an anticoagulant selected from the group consisting of low molecular weight heparins, danaparoid sodium, fondaparinux and idraparinux, comprising administering to a person in need thereof a pharmaceutically effective amount of a mutated antithrombin having substantially no anticoagulant activity, wherein said mutated antithrombin is a non-wild type mutated antithrombin that differs from plasma antithrombin by having substantially lost factor Xa inhibitory activity and thrombin inhibitory activity and an increased affinity for the anticoagulant so that said mutated antithrombin is able to bind to the anticoagulant and to shift, including in vivo, the binding between plasma antithrombin and anticoagulant, and wherein said mutated antithrombin comprises, referring to amino acid numbering of the plasma antithrombin amino acid sequence represented by SEQ ID NO: 2: at least one mutation within the region from the amino acid at position 380 to the amino acid at position 400 to provide a substantial loss of factor Xa inhibitory activity and thrombin inhibitory activity, said mutation being selected from the group consisting of an insertion between the amino acids at positions 393 and 394, a deletion of the amino acid at position 393, a deletion of the amino acid at position 394, and a deletion of the amino acids at positions 393 and 394, said mutation and at least one mutation at the glycosylation sites at the amino acid at position 96, 135, 155 or 192 to provide a loss of glycosylation and an increase in affinity for the anticoagulant compared to the amino acid sequence represented by SEQ ID NO: 2.